Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: Safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries

The Journal of Rheumatology, 10/20/2010

Gibofsky A et al. – The RADIUS registries provide a better understanding of the safety of etanercept in patients with RA in the US practice setting.


  • Adults ? 18 years of age who fulfilled 1987 American Rheumatism Association criteria for RAwere eligible for enrollment in 2 prospective, 5-year, multicenter, observational registries
  • RADIUS 1 (Rheumatoid Arthritis DMARD Intervention and Utilization Study) enrolled patients with RA who required change in treatment [either an addition or a switch of a biologic or nonbiologic disease-modifying antirheumatic drug (DMARD)]
  • In RADIUS 2, patients with RA required to start etanercept therapy at entry
  • Patients seen at frequency determined by their rheumatologist


  • SAE, SIE, and EMI occurred at rates comparable to those seen in clinical trials
  • No unexpected safety signals were observed
  • Rates for SAE, SIE, and EMI in etanercept-treated patients comparable to rates observed in patients receiving methotrexate monotherapy and did not increase with greater exposure to etanercept therapy

Print Article Summary

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List